Aclaris Therapeutics (ACRS)

• Market cap: $267M
• 1 day: -1.2%
• 5 days: 2.93%
• 1 month: 22.39%
• 3 months: 37.43%
• 6 months: 89.23%
• Year to date: -0.81%
• 1 year: -46.41%
• 5 years: -20.39%
• 10 years: -87.64%
• Sector: Healthcare
• Industry: Biotechnology

About: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Employees: 64